Language selection

Search

Patent 1055491 Summary

Third-party information liability

Some of the information on this Web page has been provided by external sources. The Government of Canada is not responsible for the accuracy, reliability or currency of the information supplied by external sources. Users wishing to rely upon this information should consult directly with the source of the information. Content provided by external sources is not subject to official languages, privacy and accessibility requirements.

Claims and Abstract availability

Any discrepancies in the text and image of the Claims and Abstract are due to differing posting times. Text of the Claims and Abstract are posted:

  • At the time the application is open to public inspection;
  • At the time of issue of the patent (grant).
(12) Patent: (11) CA 1055491
(21) Application Number: 222888
(54) English Title: PROCESS FOR THE MANUFACTURE OF BENZODIAZEPINE DERIVATIVES
(54) French Title: PROCEDE POUR LA FABRICATION DE DERIVES DE LA BENZODIAZEPINE
Status: Expired
Bibliographic Data
(52) Canadian Patent Classification (CPC):
  • 260/240.4
(51) International Patent Classification (IPC):
  • C07D 243/28 (2006.01)
  • C07D 401/04 (2006.01)
(72) Inventors :
  • HELLERBACH, JOSEPH (Not Available)
  • WALSER, ARMIN (Not Available)
(73) Owners :
  • HOFFMANN-LA ROCHE LIMITED (Canada)
(71) Applicants :
(74) Agent:
(74) Associate agent:
(45) Issued: 1979-05-29
(22) Filed Date:
Availability of licence: N/A
(25) Language of filing: English

Patent Cooperation Treaty (PCT): No

(30) Application Priority Data: None

Abstracts

English Abstract


Abstract

Benzodiazepine derivatives of formula
Image I
wherein R signifies hydrogen or alkyl,
R1 signifies hydrogen, halogen or trifluoromethyl
and R2 signifies phenyl, halophenyl or pyridyl,
and 4-oxides thereof are prepared by a novel process which
comprises reacting a benzophenone of the general formula
Image II
wherein R, R1 and R2 are as defined above
with a nitroacetic acid halide, reducing the abtained nitro-
acetyl compound of the general formula



Image III

wherein R, R1 and R2 are as defined above
to the corresponding hydroxylamine or amine derivative and
cyclizing the product thus obtained.
Benzodiazepines of formula I and 4-oxides thereof are
known compounds which are known to be useful as sedatives,
anticonvulsants and muscle relaxants.


Claims

Note: Claims are shown in the official language in which they were submitted.


THE EMBODIMENTS OF THE INVENTION IN WHICH AN EXCLUSIVE
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:

1. In a process for the manufacture of benzodiasepine derivatives of
the general formula
Image I
wherein R signifies hydrogen or alkyl with up to 7 carbon atoms, R1 signifies
hydrogen, halogen or trifluoromethyl and R2 signifies phenyl, and 4-oxides
thereof by cyclization a compound of the general formula
Image IV
wherein R, R1 and R2 are as defined above and R3 signifies hydrogen or
hydroxy the improvement which comprises preparing the compound of formula
IV by reacting a benzophenone of the general formula
Image II
wherein R, R1 and R2 are as defined above with a nitroacetic acid halide and
reducing the obtained nitroacetyl compound of the general formula
Image III



wherein R, R1 and R2 are as defined above, either
a) with about 6 g. atom of zinc per mol. of compound III in
order to obtain a compound of formula IV, wherein R3 is hydroxy, or
b) with about 10 g. atom of zinc per mol. of compound III or
catalytically in order to obtain a compound of formula IV, wherein R3 is
hydrogen.


2. A process as claimed in claim 1, wherein nitroacetic acid chloride
is used.


3. A process as claimed in claim 1, wherein the reduction is effected
with zinc.


4. A process as claimed in claim 1, wherein R1 signifies halogen.


5. A process as claimed in claim 4, wherein R1 signifies chlorine.


6. A process as claimed in any one of claims 1 - 3, wherein R2
signifies phenyl.


7. A process as claimed in claim 1, wherein R signifies methyl.


8. A process as claimed in claim 7, wherein 7-chloro-1,3-dihydro-1-
methyl-5-phenyl-2H-1,4-benzodiazepin-2-one is prepared.



Description

Note: Descriptions are shown in the official language in which they were submitted.


1~55g~9~

The present invention relates to an improved process for
the manufacture of benzodiazepine derivatives of the general
formula



~ ~ - CO



Rl N
R2




wherein R signifies hydrogen or alkyl with up to 7 carbon atoms,
Rl s;.gnifies hydrogen, halogen or
trifluoromethyl and R2 signifies phenyl, and 4-oxides thereof.
The expression "halogen" includes the four halogens fluorine,
chlorine, bromine and iodine.
In a preferred embodiment of the process in accordance
with the invention, Rl signifies halcgen, preferably chlorin~,




.,




~ .


': ', ~ ., . :' ,
.

~5549~

Especially preferred is the manufacture of 7-chloro-1,3-dihydro- - -
l-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one.
This invention relates to an improved process for the
manufacture of benzodiazepine derivatives of the general formula
R
~ N - C ~ I :


Rl C = N
R2




wherein R signi~ies hydrogen or alkyl with up to 7 carbon atoms, R
signifies hydrogen, halogen or trifluoromethyl and R2 signifies
phenyl, and 4-oxides thereof by cyclization a compound of the general
formula
R

~/N-co-cH2-NH-R3 ' '
l C=O IV

R2 :1
wherein R, Rl and R2 are as defined above and R3 signifies hydrogen or :~.
hydroxy the improvement which comprises preparing the compound of
formula IV by reacting a benzophenone of the general formula

R
NH


Rl ~ C=O II
R2 ~. .
wherein R, Rl and R2 are as definad above with a nitroacetic acid halide

and reducing the obtained nitroacetyl compound of the general formula




~ r - 3 - ~
,, : .

l~S5491


CO-CH2 -N02

Rl ~ C=O III
R2




wherein R, Rl and R2 are as defined above, either
a) wi~h about 6 g. atom of zinc per mol. of compound III in order
to obtain a compound of ~ormula IV, wherein R3 is hydroxy, or
b) with about 10 g. atom of zinc per mol. of compound III or
catalytically in order to obtain a compound of formula IV, wherein R3 is

hydrogen.
:.
': ''




,.
: :~ .




_.. .
~' ~.;~

,: ,
' ' ,.,.. : :

lC~SS~91
The reaction Or a compound o~ the general fQrmula II
with the acid halide is preferably carried out in an inert
organic solvent(such as hydrocarbons, e.g. benzene, toluene
and the liken chlorinated hydrocarbons such as chloroform,
methylene chloride and the like, ethers such as dioxane and
the like)and at temperatures from -5 to 50C.

It is expedient to use nitroacetyl chloride as the
nitroacetic acid hali~e. ~his nikroacetyl chloride can be
obtained expediently by the reaction of nitroacetic acid with
phosphoru~ pentachloride~ whereby the mixture o~ nitroacetyl
chloride and phosphorus oxyehloride can be used directly for
the acylation.

~he reduction of a compound of the form~la III can be
carried out~ e.g~ with zinc9 expedien~ly in acidic or neutral
medium and at temperatureR rrom -20~ to 100C. Depending on
the reaction condition~, i.e, the reaction time or the amount
of acid and zinc used, there is obtained a hydro~lamine
deri~ativ~ of the general formula


0-CH2-NH~H

Rl ~ ~ IV~
R2




wherein R~ Rl and R2 are as de~ined above
,:
or an amine of the general formula




...
. .

i;S4~l



H2-NH4~ ~Vb




wherein R, Rl and R2 are as defined above.
Ilfq
Amines of the formula ~ can also be obtained from the corres-
ponding nitro derivatives o~ the ~ormula III by catalytic
reduction, e.g. with palladiumJ platinum and the like.

The reduction of a compound of the formula III to a
hydroxylamine or amine derivative is expediently effected in
a solvent such as hydrocarbons, e.g. benzene, toluene,
chlorinated hydrocarbons, e.g. methylene chloride, alcohols
such as methanol, ethanol, ethers, glacial acetic acid,
aqueous acetic acid (either alone or in admixture with other
solvents, e.g. the solvents ~ust mentioned).



rme cyclisation of a hydroxylamine or amlne derivative
can be ef~ecked in acidic or alkaline medium in a known manner.


~:
Compounds of the formula I~ and N~can be cyclised


without isolation o~ same ~rom the reaction mixture.
~ .
Benzodiazepines of formula I and l~-oxides thereof are
known compounds which are known to be userul as sedatlves,
anticonvulsants and muscle relaxants.



- 5 -
!




.

~5549~

The following Examples illustrate the process in accor-
dance with the invention. All temperatures are given in C.


Example

10.5 g (0.1 mol) of nitroacetic acid are suspended in
50 ml of dry chloroform and 23 g (0.11 mol) of phosphorus
pentachloride are added at -20. The reaction mixture is
stirred for 30 minutes at -20 to -10. The clear solution
so-obtained~ together with 200 ml of a 15 ~ sodium carbonate
solution is added dropwise at 2-5 to a strongly stirred
solution of 11.6 g (0.05 mol) of 2-amino-5-chlorobenzophenone
in 100 ml of chloroform. By a rapid addition of the acid
chloride mixture, it is achieved that at no point in time does
the reaction mixture react alkaline. After effecting the
addition, the mixture is stirred at 5-10 for a further 15
~5 minuteæ. The chloroform phase is then separated, washed with
water, drled over sodium sulphate and thoroughly evaporated
(~ 30 ). The orystalline residue is suspended in ether and
filtered off under suction to give 2'-benzoyl-4'-chloro-2-
nitroa¢etanllide of meltlng point 163-166 (decomp. and
conversion into 6-chloro-~-nitro-4-phenylcarbostyril).

4 g of zinc dust are introduced in one portion into a
solution of 3.2 g (0.01 mol) of 2'-benzoyl-4'-chloro-2-nitro-
acetanillde in 100 ml of methylene chloride and 4 ml of
.




.. ...
.. . . . .. . . . . .

~SS49~

glacial acetic acid with stirring under nitrogen. The
temperature increase results in a vigorous reflux of the
solvent. After cessation of the exothermal reaction, the
mixture is stirred for a further 10 minutes and made alkaline
with dilute ammonia. The methylene chloride phase is dried
over anhydrous sodium sulphate, filtered and evaporated in
vacuo. The residue is taken up in ether and there crystallises
2'-benzoyl-4'-chloro-2-hydroxylaminoace~anilide which, after
recrystallisation from alcohol, melts at 125-128. This product
can be converted, for example by t~eatment with alcoholic hydro-
chloric acid, into 7-chloro-1,3-dihydro-5-phenyl-2H-l,~-benzo-
diazepin-2-one 4-oxide of melting point 231-233.
Example 2
. .
The nitroacetic acid chloride is prepared from 10.5 g
of nitroacetic acid and 23 g of phosphorus pentachloride accord-
ing to the proceduro described in Example 1. This acid chloride
is added dropwise at 5-10, together with 200 ml of a 15 % soda
solution, ~o a strongly stirred solution o~ 12.3 g ~0.05 mol)
of 5-chloro-2-methylaminobenzophenone in 50 ml of chloro~orm.
At the end of the addition, the mixture is stirred for a ~urther
20 minutes at 5-10. The chloroform phase is separated, washed
with water, dried over sodium sulphate and evaporated in vacuo
at 30. The residue is crystallized from ether. After
recrystallisation from methylene chloride/hexane,




~J

" . . .............. , "
. .. ... , ., . , . : .
. . . . .. .. .

~La35549~
there is obtained 2'-benzoyl-4'-chloro-N-methyl-2 nitro
acetanilide of melting point 120-123 (decomp. and conversion
into 6-chloro-1-methyl-3-nitro-4-phenylcarbostyril of mel~ing
point 212-214).
1 ml of glacial acetic acid and 2 g of zinc dust are
added to a solution of lg of 2'-benzoyl-4'-chloro-N-methyl-
2-nitroacetanilide in 15 ml of me~hylene chloride. After the
exothermal reaction, the mixture is stirred at room temperature
for a further 15 minutes. After the addition of 5 ml of conc.
ammonia, the reaction mixture is partitioned between Nater and
ether. The ether phase is extracted 3 x with 2-n hydrochloric
acid. The ~xtracts are washed with ether and are made alkaline
by addition of ammonia. The liberated bases are extracted with
methylene chlorid0. The extracts are dried over sodium sulphate
and evaporated to yield a crude product~ By chromatography on
15 g of silica gel with 10 % ethyl acetate in methylene chloride -
and crystallisation from ether/hexane, there is obtained 7-chloro-
1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one of m.p.
130-13~.




- ;-,
q~ ' .

. . .
, ...
. .
- ,, , ,,, , ,. . ,,,, ~, ,

Representative Drawing

Sorry, the representative drawing for patent document number 1055491 was not found.

Administrative Status

For a clearer understanding of the status of the application/patent presented on this page, the site Disclaimer , as well as the definitions for Patent , Administrative Status , Maintenance Fee  and Payment History  should be consulted.

Administrative Status

Title Date
Forecasted Issue Date 1979-05-29
(45) Issued 1979-05-29
Expired 1996-05-29

Abandonment History

There is no abandonment history.

Owners on Record

Note: Records showing the ownership history in alphabetical order.

Current Owners on Record
HOFFMANN-LA ROCHE LIMITED
Past Owners on Record
None
Past Owners that do not appear in the "Owners on Record" listing will appear in other documentation within the application.
Documents

To view selected files, please enter reCAPTCHA code :



To view images, click a link in the Document Description column. To download the documents, select one or more checkboxes in the first column and then click the "Download Selected in PDF format (Zip Archive)" or the "Download Selected as Single PDF" button.

List of published and non-published patent-specific documents on the CPD .

If you have any difficulty accessing content, you can call the Client Service Centre at 1-866-997-1936 or send them an e-mail at CIPO Client Service Centre.


Document
Description 
Date
(yyyy-mm-dd) 
Number of pages   Size of Image (KB) 
Description 1994-04-20 8 224
Drawings 1994-04-20 1 13
Claims 1994-04-20 2 51
Abstract 1994-04-20 2 56
Cover Page 1994-04-20 1 26